ZA931797B - Peptides and nucleic acid sequences related to the epstein barr virus - Google Patents

Peptides and nucleic acid sequences related to the epstein barr virus

Info

Publication number
ZA931797B
ZA931797B ZA931797A ZA931797A ZA931797B ZA 931797 B ZA931797 B ZA 931797B ZA 931797 A ZA931797 A ZA 931797A ZA 931797 A ZA931797 A ZA 931797A ZA 931797 B ZA931797 B ZA 931797B
Authority
ZA
South Africa
Prior art keywords
peptides
nucleic acid
ebv
antibodies
acid sequences
Prior art date
Application number
ZA931797A
Other languages
English (en)
Inventor
Jaap Michiel Middeldorp
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of ZA931797B publication Critical patent/ZA931797B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
ZA931797A 1992-03-13 1993-03-12 Peptides and nucleic acid sequences related to the epstein barr virus ZA931797B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92200721 1992-03-13

Publications (1)

Publication Number Publication Date
ZA931797B true ZA931797B (en) 1993-09-30

Family

ID=8210477

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA931797A ZA931797B (en) 1992-03-13 1993-03-12 Peptides and nucleic acid sequences related to the epstein barr virus

Country Status (13)

Country Link
US (1) US5424398A (de)
EP (2) EP1225226B1 (de)
JP (3) JP4135996B2 (de)
KR (1) KR100291247B1 (de)
AT (2) ATE222291T1 (de)
AU (1) AU666920B2 (de)
CA (1) CA2092680C (de)
DE (2) DE69334191T2 (de)
DK (2) DK0574048T3 (de)
ES (2) ES2184735T3 (de)
FI (1) FI114802B (de)
PT (1) PT574048E (de)
ZA (1) ZA931797B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330966T2 (de) * 1993-07-23 2002-06-06 Wolf, Hans DNA-Sequenzen des Epstein-Barr Virus kodierend für ein diagnostisch relevantes Virus-Hüllprotein, durch PCR erhaltene Expressionsklone und Verwendung dieses rekombinanten Antigens in diagnostischen Tests
EP0649904B1 (de) * 1993-09-14 2003-01-22 bioMérieux BV Diagnostische Reagenzien zum Nachweis von Antikörper gegen EBV
US5834747A (en) 1994-11-04 1998-11-10 Pixel Instruments Universal credit card apparatus and method
DE19526384C2 (de) * 1995-07-19 1997-07-10 Biotest Ag Rekombinante autologe Fusionsproteine des Epstein-Barr-Virus, sowie diese enthaltende Testkits zum Nachweis von Epstein-Barr-Virus-spezifischen Antikörpern
US5813500A (en) * 1996-03-25 1998-09-29 Tenneco Automotive Inc. Anti-swish mechanism for a damper
FR2765688B1 (fr) 1997-07-04 1999-09-10 Pasteur Institut Reactif de detection et de suivi des infections provoquees par le virus d'epstein-barr et ses applications
US7105496B2 (en) * 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
EP1627886A1 (de) * 1997-10-07 2006-02-22 Ono Pharmaceutical Co., Ltd. Polypeptide, die dafür kodierende cDNA und deren Verwendung
DE69940770D1 (de) 1998-03-04 2009-06-04 Biomerieux Bv Vervielfältigung und nachweis von ebv barf1 zur diagnose von nasopharyngealen karzinom
US20030064917A1 (en) * 1998-07-23 2003-04-03 Crawford Susan E. Methods and compositions for inhibiting angiogenesis
US6159950A (en) * 1998-10-16 2000-12-12 Cornell Research Foundation, Inc. Method of modulating hair growth
CA2400948A1 (en) * 2000-02-25 2001-08-30 Ludwig Institute For Cancer Research Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
AU2002361559A1 (en) * 2001-09-24 2003-04-28 University Of Pittburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diganostic methods and reagents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
JP2005530716A (ja) * 2002-03-27 2005-10-13 アメリカ合衆国 ヒトにおける癌の治療方法
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US6886670B2 (en) * 2003-09-29 2005-05-03 Tenneco Automotive Operating Company Inc. Extra support land for valve disc
DE10307517A1 (de) * 2003-02-21 2004-09-02 Mikrogen Molekularbiologische Entwicklungs-Gmbh Von Kapsidantigenen des Epstein-Barr-Virus abgeleitete Peptide und ihre Verwendung
US6899207B2 (en) 2003-09-29 2005-05-31 Tenneco Automotive Operating Company Inc. Extra support area for valve disc
AU2005255019B2 (en) * 2004-06-12 2011-05-19 Oregon Health And Science University Compositions and methods for diagnosis and treatment of orthopoxviruses
US7278987B2 (en) * 2004-07-09 2007-10-09 Anthony Solazzo Ergonomic urological catheterization/irrigation tray
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
EP2311531A1 (de) 2005-12-01 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Antivirale Griffithsin-Verbindungen, Zusammensetzungen und Verwendungsverfahren dafür
EP2172210A1 (de) 2005-12-23 2010-04-07 Partnership&Corp. Technology Transfer Synthetische Peptide zur Verwendung als Inhibitoren der Neurotransmiter-Sekretion
US7868228B2 (en) 2006-01-31 2011-01-11 Monsanto Technology Llc Phosphopantetheinyl transferases from bacteria
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8748170B2 (en) 2008-07-25 2014-06-10 University of Pittsburgh—of the Commonwealth System of Higher Education Polypeptides derived from cyclin B1 and uses thereof
DK2337791T3 (da) 2008-10-14 2013-11-04 Monsanto Technology Llc Anvendelse af fedtsyredesaturaser fra Hemiselmis SPP
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
DK2451279T3 (da) 2009-07-06 2019-05-20 Aerpio Therapeutics Inc Benzosulfonamid derivater forbindelser deraf og deres brug til at forhindre metastaser af cancerceller
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
WO2013025479A1 (en) 2011-08-16 2013-02-21 Emory University Jaml specific binding agents, antibodies, and uses related thereto
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
EP2813849A1 (de) * 2013-06-10 2014-12-17 Charité-Universitätsmedizin Berlin (Charité) EBV-spezifische Immunsignatur als Diagnosemarker bei chronischem Erschöpfungssyndrom (CFS)
US11034736B2 (en) 2014-01-09 2021-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-viral cnidarins
ES2781085T3 (es) 2015-02-10 2020-08-28 Us Health Mutantes de griffithsina
EP3256144B1 (de) 2015-02-13 2021-03-24 The Board of Trustees of the University of Illionis Peptidhemmung von ccr3-vermittelten krankheiten oder zuständen
AU2016281189B2 (en) 2015-06-15 2019-03-07 Hudson Institute of Medical Research IL-37 variants
US10703786B2 (en) 2015-10-30 2020-07-07 The University Of Melbourne Methods and compositions for improving glucose metabolism
CN108490177B (zh) * 2018-02-08 2020-12-29 深圳市新产业生物医学工程股份有限公司 鼻咽癌抗体检测试剂、其制备方法及鼻咽癌检测试剂盒
JP2022543056A (ja) 2019-07-29 2022-10-07 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 創傷治癒を促進するための組成物および方法
WO2021123173A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Il-37 fusion proteins and uses thereof
WO2022109053A1 (en) 2020-11-18 2022-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tyrosyl-lock peptides
WO2023192802A1 (en) 2022-04-01 2023-10-05 The Board Of Trustees Of The University Of Illinois Notch1 and notch4 decoys and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45285T1 (de) * 1983-11-07 1989-08-15 Wistar Inst Durch antiidiotype antikoerper induzierte immune antwort zu tumoren und viren.
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
IE873041L (en) * 1987-11-11 1989-05-11 Ailbe Brennan Viral antigens, diagnostic assay therefor and vaccines¹containing them
WO1991002091A1 (en) * 1989-08-10 1991-02-21 Northwestern University Method of identifying herpesviruses and oligonucleotides for use therein
WO1991008224A1 (en) * 1989-11-24 1991-06-13 The Council Of The Queensland Institute Of Medical Research Im peptides
ES2064082T3 (es) * 1989-12-20 1995-01-16 Schering Corp Proteinas bcrf1 como inhibidores de interferon-gamma.
JPH04310861A (ja) * 1991-04-09 1992-11-02 Kazuo Yanagi 抗ｅｂｎａ抗体の測定方法および抗ｅｂｎａ抗体測定キット

Also Published As

Publication number Publication date
PT574048E (pt) 2002-12-31
DE69334191D1 (de) 2008-01-17
JP4135996B2 (ja) 2008-08-20
FI931109A (fi) 1993-09-14
CA2092680C (en) 2006-08-08
FI931109A0 (fi) 1993-03-12
CA2092680A1 (en) 1993-09-14
DK0574048T3 (da) 2002-12-16
EP1225226A1 (de) 2002-07-24
EP0574048B1 (de) 2002-08-14
KR930019829A (ko) 1993-10-19
DK1225226T3 (da) 2008-04-14
DE69334191T2 (de) 2008-11-27
EP0574048A2 (de) 1993-12-15
ATE380243T1 (de) 2007-12-15
JP4365440B2 (ja) 2009-11-18
AU666920B2 (en) 1996-02-29
EP0574048A3 (de) 1994-03-02
JP2004261183A (ja) 2004-09-24
KR100291247B1 (ko) 2001-06-01
EP1225226B1 (de) 2007-12-05
ES2184735T3 (es) 2003-04-16
ATE222291T1 (de) 2002-08-15
FI114802B (fi) 2004-12-31
DE69332197D1 (de) 2002-09-19
JP4106041B2 (ja) 2008-06-25
JP2008261851A (ja) 2008-10-30
ES2298325T3 (es) 2008-05-16
US5424398A (en) 1995-06-13
JPH0690787A (ja) 1994-04-05
AU3515293A (en) 1993-09-16
DE69332197T2 (de) 2003-04-17

Similar Documents

Publication Publication Date Title
ZA931797B (en) Peptides and nucleic acid sequences related to the epstein barr virus
UA50829C2 (uk) Очищений поліпептид, що містить антиген вірусу гепатиту с, полінуклеотид, вектор, клітини, система експресії, моноклональне антитіло, препарат поліклональних антитіл, нуклеотидна проба, аналітичні набори, спосіб виявлення нуклеїнових кислот, способи імуноаналізу, вакцина, спосіб одержання антитіл
ES8602119A1 (es) Metodo para preparar inmunoglobulinas en celulas hospedantes recombinantes
CA2079912A1 (en) Hepatitis c virus epitopes
EP0460076A4 (en) Genetically engineered immunoglobulins
EP0151079A3 (de) Vakzin gegen das Epstein-Barr-Virus
DK61595A (da) Rekombinant DNA-molekyler, værtscelletransformering dermed, værtsceller indeholdende disse samt fremgangsmåde til fremstilling af et polypeptid af IFN-alfa-typen
HU9303703D0 (en) Hepatitis c virus (hcv) polypeptides
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
AU8700291A (en) Hcv-specific peptides, agents therefor and the use thereof
AU3192889A (en) T cell activation markers
EP0201716A3 (en) Expression of immunologically reactive viral proteins
CA2057052A1 (en) Enterically transmitted non-a/non-b hepatitis viral agent and characteristic epitopes thereof
EP0540645A4 (en) Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells
MY135991A (en) A vaccine-induced hepatits b viral strain and uses thereof
HK1017364A1 (en) A membrane protein polypeptide having pre-b cell growth-supporting ability and a gene thereof
EP0432220A4 (en) Vaccines and diagnostic assays for haemophilus influenzae
DK326289D0 (da) Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden
JO1885B1 (en) A method for purifying surface serum for viral hepatitis B, consisting of Bryce 2 peptide
EP0503950A3 (en) Method of purifying recombinant hepatitis b virus surface proteins from recombinant cells
Roeckel et al. Biochemical characterization of two Epstein-Barr virus early antigen-associated phosphopolypeptides
CA2084521A1 (en) Hepatitis c virus antigen polypeptide, production method therefor, and antibody detection method
EP0754755A3 (de) Rekombinante autologe Fusionsproteine des Epstein-Barr-Virus, diese enthaltende Testkits und Verfahren zum Nachweis von Epstein-Barr-Virus-spezifischen Antikörpern
WO1988009809A3 (en) Cell system for expression of recombinant protein without production of virus
Schultz et al. Expression and Analysis of EBV gp350 in the Yeast Saccharomyces Cerevisiae